BRAFV600E and TERT promoter mutations and their impact on recurrent papillary thyroid carcinoma progression
Papillary thyroid carcinoma (PTC) is the most prevalent histological subtype of thyroid cancer. However, it remains unclear whether BRAFV600E, TERT promoter (TERT-p), and certain pathological markers, such as loss of polarity/loss of cell cohesiveness (LOP/LCC), tall cells, mitotic count, and Ki-67...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2025-07-01
|
| Series: | Endocrine Connections |
| Subjects: | |
| Online Access: | https://ec.bioscientifica.com/view/journals/ec/14/7/EC-25-0116.xml |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850038183877672960 |
|---|---|
| author | Nguyen Thi Nhung Van Dong Hoang Zhanna Mussazhanova Hirokazu Kurohama Le Ngoc Ha Katsuya Matsuda Van Phu Thang Nguyen Ngo Thi Minh Hanh Thi Ngoc Anh Nguyen Masahiro Nakashima |
| author_facet | Nguyen Thi Nhung Van Dong Hoang Zhanna Mussazhanova Hirokazu Kurohama Le Ngoc Ha Katsuya Matsuda Van Phu Thang Nguyen Ngo Thi Minh Hanh Thi Ngoc Anh Nguyen Masahiro Nakashima |
| author_sort | Nguyen Thi Nhung |
| collection | DOAJ |
| description | Papillary thyroid carcinoma (PTC) is the most prevalent histological subtype of thyroid cancer. However, it remains unclear whether BRAFV600E, TERT promoter (TERT-p), and certain pathological markers, such as loss of polarity/loss of cell cohesiveness (LOP/LCC), tall cells, mitotic count, and Ki-67 labeling index (LI) in recurrent tumors, are associated with clinical outcomes in patients with PTC after reoperation for recurrent PTC. This study investigates the impact of BRAFV600E and TERT-p mutations on progression-free survival (PFS) after reoperation for recurrent PTC. Cox regression analysis was employed to identify parameters associated with PFS. During a mean follow-up period of 27 months after reoperation, 39 patients (21.3%) experienced disease progression. Coexistence of BRAFV600E and TERT-p mutations (double mutation: Dmut) was observed in 21.3% of patients. TERT-p, Dmut, LOP/LCC (≥10%), mitotic count (≥3 per 2 mm2), and Ki-67 LI were found to be significantly associated with disease progression in unadjusted analyses. In a multivariable analysis, these associations remained significant, with hazard ratios and 95% confidence intervals for TERT-p, Dmut, LOP/LCC, mitotic count, and Ki-67 LI being 5.98 (2.31–15.5), 5.44 (2.21–13.3), 6.81 (2.00–23.2), 5.05 (2.07–12.3), and 5.85 (2.48–13.7), respectively. Extranodal extension was associated with disease progression in both unadjusted and multivariable analyses. TERT-p, Dmut, Ki-67 LI, LOP/LCC, mitotic count, and extranodal extension were identified as independent risk factors for poor PFS after reoperation. Close surveillance following reoperation is recommended for patients exhibiting these factors. |
| format | Article |
| id | doaj-art-e74df8f8e4c24df285a7abc9ba2c19ce |
| institution | DOAJ |
| issn | 2049-3614 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | Endocrine Connections |
| spelling | doaj-art-e74df8f8e4c24df285a7abc9ba2c19ce2025-08-20T02:56:39ZengBioscientificaEndocrine Connections2049-36142025-07-0114710.1530/EC-25-01161BRAFV600E and TERT promoter mutations and their impact on recurrent papillary thyroid carcinoma progressionNguyen Thi Nhung0Van Dong Hoang1Zhanna Mussazhanova2Hirokazu Kurohama3Le Ngoc Ha4Katsuya Matsuda5Van Phu Thang Nguyen6Ngo Thi Minh Hanh7Thi Ngoc Anh Nguyen8Masahiro Nakashima9Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto, Nagasaki, JapanMedical Oncology Clinical Trial Unit Fiona Stanley Hospital, Murdoch, Western Australia, AustraliaDepartment of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto, Nagasaki, JapanDepartment of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto, Nagasaki, JapanDepartment of Nuclear Medicine, 108 Military Central Hospital, Ha Noi, VietnamDepartment of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto, Nagasaki, JapanDepartment of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto, Nagasaki, JapanDepartment of Pathology, 108 Military Central Hospital, Ha Noi, VietnamDepartment of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto, Nagasaki, JapanDepartment of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto, Nagasaki, JapanPapillary thyroid carcinoma (PTC) is the most prevalent histological subtype of thyroid cancer. However, it remains unclear whether BRAFV600E, TERT promoter (TERT-p), and certain pathological markers, such as loss of polarity/loss of cell cohesiveness (LOP/LCC), tall cells, mitotic count, and Ki-67 labeling index (LI) in recurrent tumors, are associated with clinical outcomes in patients with PTC after reoperation for recurrent PTC. This study investigates the impact of BRAFV600E and TERT-p mutations on progression-free survival (PFS) after reoperation for recurrent PTC. Cox regression analysis was employed to identify parameters associated with PFS. During a mean follow-up period of 27 months after reoperation, 39 patients (21.3%) experienced disease progression. Coexistence of BRAFV600E and TERT-p mutations (double mutation: Dmut) was observed in 21.3% of patients. TERT-p, Dmut, LOP/LCC (≥10%), mitotic count (≥3 per 2 mm2), and Ki-67 LI were found to be significantly associated with disease progression in unadjusted analyses. In a multivariable analysis, these associations remained significant, with hazard ratios and 95% confidence intervals for TERT-p, Dmut, LOP/LCC, mitotic count, and Ki-67 LI being 5.98 (2.31–15.5), 5.44 (2.21–13.3), 6.81 (2.00–23.2), 5.05 (2.07–12.3), and 5.85 (2.48–13.7), respectively. Extranodal extension was associated with disease progression in both unadjusted and multivariable analyses. TERT-p, Dmut, Ki-67 LI, LOP/LCC, mitotic count, and extranodal extension were identified as independent risk factors for poor PFS after reoperation. Close surveillance following reoperation is recommended for patients exhibiting these factors.https://ec.bioscientifica.com/view/journals/ec/14/7/EC-25-0116.xmlrecurrent papillary thyroid carcinomadisease progressiontertloss of polarity/loss of cell cohesivenessmitosis |
| spellingShingle | Nguyen Thi Nhung Van Dong Hoang Zhanna Mussazhanova Hirokazu Kurohama Le Ngoc Ha Katsuya Matsuda Van Phu Thang Nguyen Ngo Thi Minh Hanh Thi Ngoc Anh Nguyen Masahiro Nakashima BRAFV600E and TERT promoter mutations and their impact on recurrent papillary thyroid carcinoma progression Endocrine Connections recurrent papillary thyroid carcinoma disease progression tert loss of polarity/loss of cell cohesiveness mitosis |
| title | BRAFV600E and TERT promoter mutations and their impact on recurrent papillary thyroid carcinoma progression |
| title_full | BRAFV600E and TERT promoter mutations and their impact on recurrent papillary thyroid carcinoma progression |
| title_fullStr | BRAFV600E and TERT promoter mutations and their impact on recurrent papillary thyroid carcinoma progression |
| title_full_unstemmed | BRAFV600E and TERT promoter mutations and their impact on recurrent papillary thyroid carcinoma progression |
| title_short | BRAFV600E and TERT promoter mutations and their impact on recurrent papillary thyroid carcinoma progression |
| title_sort | brafv600e and tert promoter mutations and their impact on recurrent papillary thyroid carcinoma progression |
| topic | recurrent papillary thyroid carcinoma disease progression tert loss of polarity/loss of cell cohesiveness mitosis |
| url | https://ec.bioscientifica.com/view/journals/ec/14/7/EC-25-0116.xml |
| work_keys_str_mv | AT nguyenthinhung brafv600eandtertpromotermutationsandtheirimpactonrecurrentpapillarythyroidcarcinomaprogression AT vandonghoang brafv600eandtertpromotermutationsandtheirimpactonrecurrentpapillarythyroidcarcinomaprogression AT zhannamussazhanova brafv600eandtertpromotermutationsandtheirimpactonrecurrentpapillarythyroidcarcinomaprogression AT hirokazukurohama brafv600eandtertpromotermutationsandtheirimpactonrecurrentpapillarythyroidcarcinomaprogression AT lengocha brafv600eandtertpromotermutationsandtheirimpactonrecurrentpapillarythyroidcarcinomaprogression AT katsuyamatsuda brafv600eandtertpromotermutationsandtheirimpactonrecurrentpapillarythyroidcarcinomaprogression AT vanphuthangnguyen brafv600eandtertpromotermutationsandtheirimpactonrecurrentpapillarythyroidcarcinomaprogression AT ngothiminhhanh brafv600eandtertpromotermutationsandtheirimpactonrecurrentpapillarythyroidcarcinomaprogression AT thingocanhnguyen brafv600eandtertpromotermutationsandtheirimpactonrecurrentpapillarythyroidcarcinomaprogression AT masahironakashima brafv600eandtertpromotermutationsandtheirimpactonrecurrentpapillarythyroidcarcinomaprogression |